September 17, 2016 By Jolie Higazi
Johnson & Johnson (J&J) announced it has entered into a definitive agreement to acquire Abbott Medical Optics (AMO) for $4.325 billion in cash. AMO’s business segments include cataract surgery, laser refractive surgery, and consumer eye health, and reported sales in 2015 were $1.1 billion, according to the company.
“We’ve been keeping our eye on the eye health space for quite some time,” said Ashley McEvoy, company group chairman, responsible for Johnson & Johnson’s Vision Care Companies. “We really look to eye health as it’s one of the largest health care segments, growing north of 5%. With the acquisition of Abbott Medical Optics’ strong and differentiated surgical ophthalmic portfolio, coupled with our world-leading ACUVUE contact lens business, we will become a more broad-based leader in vision care.
“Importantly, with this acquisition we will enter cataract surgery – one of the most commonly performed surgeries and the number one cause of preventable blindness,” McEvoy added.
AMO is widely known for its IOLs and specialty in cataract surgery. With more than 100 million eyes worldwide compromised by cataract-related visual deficiencies, cataracts are of the most common surgeries performed and are the primary cause of preventable blindness.
In the refractive world, AMO also has advanced LASIK technologies designed which are aimed to enhance surgeon productivity and correct myopia, presbyopia, and astigmatism.
The acquisition also includes AMO’s consumer eye health products, which include over-the-counter dry eye drops, as well as cleaning solutions for contact lenses.
The transaction is expected to close in the first quarter of 2017. Following the expected closing, sales will be reported in the medical devices segment as a separate platform within vision care. The net impact of the acquisition is not expected to impact Abbott’s overall targeted ongoing earnings per share in 2017, according to prepared statements from the companies.
“We’ve been actively and strategically shaping our portfolio, which has recently focused on developing leadership positions in cardiovascular devices and expanding diagnostics,” said Miles D. White, chairman and chief executive officer, Abbott. “Our vision care business will be well-positioned for continued success and advancement with Johnson & Johnson, and I’d like to thank our employees for building a successful business.”